These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 19551544

  • 1. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A.
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [Abstract] [Full Text] [Related]

  • 2. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [Abstract] [Full Text] [Related]

  • 3. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T, Dehghan-Kooshkghazi M.
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 Feb; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 9. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [Abstract] [Full Text] [Related]

  • 10. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
    Wang Y, Mao WW, Chen YJ, Li MZ, Qiao J, Wang LN.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
    [Abstract] [Full Text] [Related]

  • 11. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M.
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [Abstract] [Full Text] [Related]

  • 12. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, Paşaoğlu H.
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [Abstract] [Full Text] [Related]

  • 13. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
    Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V.
    Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, Xu L, Chen Z.
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R.
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.